TELA Bio Q3 revenue misses estimates

TELA Bio

13/11/2025 21:11

Overview

TELA Bio Q3 2025 revenue grows 9% yr/yr to $20.7 mln, missing analyst expectations

Company revises full-year 2025 revenue guidance to at least 16% growth over 2024

TELA Bio secures $70 mln credit facility from Perceptive Advisors

Outlook

TELA Bio projects full-year 2025 revenue to grow at least 16% over 2024

Company expects strategic changes to support growth in 2026

Result Drivers

NEW CUSTOMERS - Revenue growth driven by addition of new customers and increased international sales

PRODUCT MIX SHIFT - Decrease in average selling prices for hernia products due to shift in product mix towards smaller-sized units

SALES ORGANIZATION CHANGES - Strategic changes in sales organization contributing to growth, per CEO Antony Koblish

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$20.69 mln
$21.80 mln (5 Analysts)
Q3 Net Income
-$8.60 mln
Q3 Basic EPS
-$0.19
Q3 Gross Profit
$13.97 mln
Q3 Income From Operations
-$7.55 mln
Q3 Operating Expenses
$21.52 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for TELA Bio Inc is $6.00, about 81% above its November 12 closing price of $1.14

Press Release: ID:nGNX68l0Bz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)